An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC
Keywords: PROSPER trial, enzalutamide, nonmetastatic CRPC
An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC
Summary
Maha H.A. Hussain, MBChB, provides an overview of the PROSPER trial, which tested the efficacy and safety of enzalutamide in the setting of nonmetastatic CRPC. She details the trial’s design, materials, and data.
The trial hypothesized that enzalutamide would delay metastases development in men with M0 CRPC and rapidly rising PSA. Subsequently, this would result in a delay of cancer-related morbidity and prolonged overall survival.
The trial conclusions showed that enzalutamide resulted in a clinically meaningful 71% reduction in risk of progressing to M1 CRPC, significantly delayed PSA progression, and is generally well-tolerated. While the hypothesized benefit to overall survivorship was not reached in the first interim analysis, there was a trend of 20% lower risk of death in the enzalutamide arm than the placebo arm.
Following Dr. Hussain’s presentation, she and E. David Crawford, MD, provide further discourse.
ABOUT THE AUTHOR
Maha H. Hussain, MD, is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology of the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago. She is also Deputy Director of the Robert H. Lurie Comprehensive Cancer Center. In this role, Hussain plays a critical role in establishing the overall strategic direction, policy and priorities of the Lurie Cancer Center.. She is also a practicing oncologist and clinical researcher.
Dr. Hussain’s research efforts are focused on the development of novel therapeutics integrating scientific advances into clinical trials for prostate and bladder cancer. Her extensive national scientific leadership roles include serving as Co-Chair of the Prostate Cancer Subcommittee/Genitourinary Cancer Committee of SWOG, where she guided research in areas of advanced prostate cancer that led to changing standards of care. Among other positions, she has served as a member and Chair of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program and as a member and Chair of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Prior to joining the Lurie Cancer Center in September 2016, she was Associate Director for Clinical Research at the University of Michigan Cancer Center.
